Patients with severe nonthyroidal illness (NTI) often have decreased serum thyroxin (T4) concentrations and sometimes have decreased free T4 (Fr4) and increased tumor necrosis factor-a (TNF-a) concentrations. We evaluated four commercial methods for measuring FT4 [ The low-T4 syndrome, defined by thyroid tests showing decreased total T4 and T3 concentrations and normal thyroid-stimulating hormone (TSH) concentrations, has been reported in 30-50% of patients admitted to intensive care units (1). The mortality in these patients is inversely correlated with the initial T4 concentration and is between 15% and 84% (2).
Nonthyroidal
illness (NTI) often results in decreased serum triiodothyronine (T3) and sometimes causes reduced serum thyroxin (T4), referred to as the low-T4
syndrome.2
The low-T4 syndrome, defined by thyroid tests showing decreased total T4 and T3 concentrations and normal thyroid-stimulating hormone (TSH) concentrations, has been reported in 30-50% of patients admitted to intensive care units (1). The mortality in these patients is inversely correlated with the initial T4 concentration and is between 15% and 84% (2).
The true serum concentration of free T4 (FF4) in patients with the low-T4 syndrome is controversial. Studies have documented decreased FF, concentrations by equilibrium dialysis (3, 4), ultrafiltration (5), and radioimmunoassay (RIA) methods (3, 5-7), and found normal Fr4 concentrations by these same methods (7, 8) . Increased 
Results
The mean T4 concentration for the euthyroid control group was within the normal range (Table 1) . Mean T4 was significantly lower for the hypothyroid (P <0.01) and the NTI (P <0.001) groups than for the euthyroid control group. Only one patient in the euthyroid group had a T4 slightly below normal. In the hypothyroid group, 50% had T4 values below normal; these patients were classified as having overt hypothyroidism and the remaining patients were classified as having subclinical hypothyroidism.
Of the NTI group, 17 (41.5%) had T4 values below normal and were classified as having the low-T4 syndrome.
Of these 17 patients, 10 (59%) died during the study.
The mean TSH concentration for the hypothyroid group was markedly increased above the normal range ( Table 1 ). The NTI group had a normal mean TSH value; one patient was found to have severe hypothyroidism, with an FT4 concentration of 1.3 pmol/L and a TSH concentration of 27 milli-int. unitsfL on initial screening. This patient, who eventually died, was excluded from the study.
The mean FF1 for the euthyroid group was significantly higher (P <0.001) than that for the hypothyroid group and not significantly different from the NTI group. In the euthyroid group, FF1 correlated well with all methods of FT4 measurement (r = 0.77-0.83).
FF1
also correlated well with FT4 in the hypothyroid group (r = 0.75-0.94). Correlation of FF1 and FF4 was poor in the NT! group (Table 2) . The mean FT4 values obtained by the four methods lower for the hypothyroid (P <0.001) and the NTI (P <0.02) groups than for the control group. Figure 1 shows the results of the individual measurements of the NTI patients. Only four (9.8%) of the NT! group had AbbOtt Fr4 values below normal for the Abbott assay, and two of these were receiving dopamine therapy.
By the Amersham Amerlex-MAB method, the mean FF4 value for the NT! group was significantly lower (P <0.01) than that for the euthyroid group. Twelve (29.3%) of the NT! group had FT4 values that were below normal for the Amersham assay, and two of these were receiving dopamine therapy.
When we measured FT4 by the Nichols method, the mean FT4 of the NT! group was higher than the mean of the euthyroid patients, but this difference was not statistically significant. The Nichols method gave results significantly higher (paired t-tests) than those from other methods. Only one (2.4%) of the NT! patients had an FT4 value that was less than normal for the Nichols method. This patient had a low FT4 concentration by all methods and was receiving dopamine.
The mean NT! group FT4 value by the DPC kit was significantly lower (P <0.001) than that of the euthyroid group. The DPC method yielded the highest percentage of NT! patients (61%) with FT4 concentrations lower than normal.
The mean T3 concentration in the NT! group was significantly (P <0.001) lower than that in the euthyreid group (Table 1) . TNF-a concentrations were <0.70 pmol/L in all of the 12 control subjects tested and in 11 of the NT! group. TNF-a was measurable in 13 NT! patients; the range of the detectable values was very broad, 0.7-20 pmol/L (mean 10.5, SD 6.5).
We obtained Apache II scores for 40 of the 41 NT! patients in an attempt to objectively evaluate a patient's illness by using standard physiological measurements. The mean Apache II score was 21.1 (SD 6.9, range for the Nichols FT4 assay (r = -0.32) was not significant.
A positive con-elation was also seen between TNF-a and Abbott VT! (r = 0.70, P <0.02).
The within-and between-assay CVs for the four FT4 assays are summarized in For the large clinical laboratory, this improved capability should easily justify the high initial cost of the system or increased per-tube cost of the reagents, given the concomitant savings in labor costs and record keeping for quality control.
In conclusion, the true FT4 concentration in NT! seems dependent on the assay method used. VT! correlated poorly with assayed FT4 concentration in NT! independently of the FT4 method used. Finally, despite the relationship between T4 concentrations and mortality (2), we found that Apache I! scores did not correlate with FT4 concentrations.
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